


Claims:

1. A compound as shown in formula I, and the solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof:



I

wherein:

L₁ is selected from -NR⁶CON(R⁷)-, of which NR⁶ is connected with the nitrogen-containing heteroaryl substituted by R¹, R², R³;

L₂ is selected from C1-C4 alkylene, wherein the alkylene can be optionally substituted by one or more G1;

L₃ is -O-;

R¹, R², R³ are each independently selected from hydrogen, halogen and C1-C4 alkyl, wherein the alkyl is optionally substituted by one or more substituents selected from halogen;

R⁴ is selected from hydrogen, halogen, -NR⁸R⁹, -OR¹⁰;





R⁵ is selected from hydrogen, halogen and C1-C4 alkyl;

R⁶, R⁷ are each independently selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl;

G1 is selected from halogen, C1-C4 alkyl, -NR⁸R⁹, -OR¹⁰, wherein the alkyl is optionally substituted by one or more substituents selected from halogen, -NR¹¹R¹², -OR¹⁶;

R⁸, R⁹, R¹⁰, R¹¹, R¹² and R¹⁶ are each independently selected from hydrogen, C1-C4 alkyl and C1-C4 haloalkyl;

wherein the following compounds (1) to (4) are excluded:



2. The compound according to claim 1, and the solvates, stable isotopic derivatives or

pharmaceutically acceptable salts thereof,

wherein:

L₁ is selected from -NR⁶CON(R⁷)-, of which NR⁶ is connected with the nitrogen-containing heteroaryl substituted by R¹, R², R³;

L₂ is selected from C1-C4 alkylene, wherein the alkylene can be optionally substituted by one or more G1;

L₃ is -O-;

R¹, R², R³ are each independently selected from hydrogen and halogen;


R⁴ is selected from hydrogen and halogen;

R⁵ is selected from hydrogen, halogen and C1-C4 alkyl, and is located at the para position of L₃;


R⁶, R⁷ are each independently selected from hydrogen and C1-C4 alkyl;

G1 is selected from halogen, C1-C4 alkyl, wherein the alkyl is optionally substituted by one or more substituents selected from halogen, -NR¹¹R¹², -OR¹⁶;

R¹¹, R¹² and R¹⁶ are each independently selected from hydrogen, C1-C4 alkyl and C1-C4 haloalkyl; wherein the following compounds (1) to (4) are excluded:



3. The compound according to claim 1, and the solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof, characterized in that the compounds are selected from:



4. A pharmaceutical composition comprising the compound according to any one of claims 1-3 or the solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable carriers, diluents and excipients.

5. Use of the compound according to any one of claims 1-3 or the solvates, stable isotopic

derivatives or pharmaceutically acceptable salts thereof, or the pharmaceutical composition according to claim 4, in the preparation of a medicament for the treatment or prevention of TRK mediated diseases, wherein the TRK mediated diseases are selected from the group consisting of hematological malignancies, lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer and glioma.